Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Statistics in Medicine|August 30, 2008
Bayesian adaptive model selection for optimizing group sequential clinical trialsJ Kyle Wathen, Peter F Thall
Journal of Biopharmaceutical Statistics|June 2, 2012
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomesPeter F Thall, Hoang Q Nguyen
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Some ethical issues in phase II trials in acute leukemiaPeter F Thall, Elihu H Estey
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Current Opinion in Oncology|June 6, 2008
Bayesian designs to account for patient heterogeneity in phase II clinical trialsPeter F Thall, J Kyle Wathen
Biometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying Yuan
Journal of the Royal Statistical Society. Series C, Applied Statistics|May 21, 2019
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event timesJuhee Lee, Peter F Thall, Katy Rezvani
Clinical Trials (London, England)|December 19, 2023
Risk-benefit trade-offs and precision utilities in phase I-II clinical trialsPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|October 12, 2021
Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroupsJuhee Lee, Peter F Thall, Pavlos Msaouel
Statistics in Biosciences|July 30, 2010
Evaluating the Impact of Prior Assumptions in Bayesian BiostatisticsSatoshi Morita, Peter F Thall, Peter Müller
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Statistics in Medicine|August 30, 2008
Bayesian adaptive model selection for optimizing group sequential clinical trialsJ Kyle Wathen, Peter F Thall
Journal of Biopharmaceutical Statistics|June 2, 2012
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomesPeter F Thall, Hoang Q Nguyen
Clinical Advances in Hematology & Oncology : H&O|March 25, 2006
Some ethical issues in phase II trials in acute leukemiaPeter F Thall, Elihu H Estey
Biometrics|October 28, 2018
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase IIIAndrew G Chapple, Peter F Thall
Current Opinion in Oncology|June 6, 2008
Bayesian designs to account for patient heterogeneity in phase II clinical trialsPeter F Thall, J Kyle Wathen
Biometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying Yuan
Journal of the Royal Statistical Society. Series C, Applied Statistics|May 21, 2019
Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event timesJuhee Lee, Peter F Thall, Katy Rezvani
Clinical Trials (London, England)|December 19, 2023
Risk-benefit trade-offs and precision utilities in phase I-II clinical trialsPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|October 12, 2021
Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroupsJuhee Lee, Peter F Thall, Pavlos Msaouel
Statistics in Biosciences|July 30, 2010
Evaluating the Impact of Prior Assumptions in Bayesian BiostatisticsSatoshi Morita, Peter F Thall, Peter Müller
Pageof 19